{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:08:27Z","timestamp":1761520107328,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.clcc.2016.09.004","type":"journal-article","created":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T01:03:25Z","timestamp":1474333405000},"page":"e119-e122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine"],"prefix":"10.1016","volume":"16","author":[{"given":"Jeffrey L.","family":"Turner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spero R.","family":"Cataland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Arango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2014","series-title":"Gemzar (Gemcitabine) [Prescribing Information]","key":"10.1016\/j.clcc.2016.09.004_bib1"},{"key":"10.1016\/j.clcc.2016.09.004_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00873232","article-title":"Phase II trial of gemcitabine (2,2\u2032-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas","volume":"12","author":"Casper","year":"1994","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clcc.2016.09.004_bib3","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/jnci\/89.24.1895","article-title":"Gemcitabine-induced hemolytic uremic syndrome: a case report","volume":"89","author":"Brodowicz","year":"1997","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clcc.2016.09.004_bib4","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1023\/A:1008467914836","article-title":"Hemolytic-uremic syndrome caused by gemcitabine","volume":"9","author":"Nackaerts","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2016.09.004_bib5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0272-6386(99)70194-0","article-title":"Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine","volume":"33","author":"Flombaum","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clcc.2016.09.004_bib6","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2","article-title":"A\u00a0review of hemolytic uremic syndrome in patients treated with gemcitabine therapy","volume":"85","author":"Fung","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2016.09.004_bib7","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1053\/ajkd.2002.35758","article-title":"Gemcitabine-associated hemolytic uremic syndrome","volume":"40","author":"Walter","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clcc.2016.09.004_bib8","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.20290","article-title":"Gemcitabine-associated thrombotic microangiopathy","volume":"100","author":"Humphreys","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2016.09.004_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00277-004-0938-8","article-title":"Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution","volume":"84","author":"Muller","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clcc.2016.09.004_bib10","first-page":"179","article-title":"Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature","volume":"26","author":"Desrame","year":"2005","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.clcc.2016.09.004_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome","volume":"71","author":"Glezerman","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.clcc.2016.09.004_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5009\/gnl.2014.8.1.109","article-title":"Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature","volume":"8","author":"Lee","year":"2014","journal-title":"Gut Liver"},{"key":"10.1016\/j.clcc.2016.09.004_bib13","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2016.09.004_bib14","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2016.09.004_bib15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the Blood Center of Wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"Am J Hematol"},{"year":"2004","series-title":"Mutamycin (Mitomycin C) [Prescribing Information]","key":"10.1016\/j.clcc.2016.09.004_bib16"},{"key":"10.1016\/j.clcc.2016.09.004_bib17","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clcc.2016.09.004_bib18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.clcc.2016.09.004_bib19","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood-2013-11-516237","article-title":"How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clcc.2016.09.004_bib20","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Al Ustwani","year":"2014","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.clcc.2016.09.004_bib21","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bjh.12686","article-title":"Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy","volume":"164","author":"Starck","year":"2014","journal-title":"Br J Haematol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002816301785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002816301785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:04:44Z","timestamp":1761519884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002816301785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1533002816301785"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2016.09.004","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2016.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}